Join
Live feed
·
PRReleasevia Quantisnow
Tharimmune Inc. logo

Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl

ByQuantisnow·Wall Street's wire, on your screen.
THAR· Tharimmune Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track THAR (Tharimmune Inc.) and more on Quantisnow.